In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Pharmacotherapy in Older People

Online training course by the ESC Working Group on Cardiovascular Pharmacotherapy

14/10/2021 13:00 15/10/2021 16:45 Europe/Paris Pharmacotherapy in Older People

Access event page

ESC Working Group on Cardiovascular Pharmacotherapy DD/MM/YYYY
Pharmacology and Pharmacotherapy


The ESC Working Group on Cardiovascular Pharmacotherapy presents an engaging and interactive course to improve the professional knowledge and skills on cardiovascular pharmacotherapy in older patients.


course.jpgIn Europe and the Western World in particular, the proportion of older people is dramatically increasing, which is predicted to add tremendous extra pressure to the strained healthcare systems.

Cardiovascular drugs are among the most prevalent drugs administered to older people. In particular diuretics, antihypertensives, NOACs, antiarrhythmics, lipid-lowering and glucose-lowering drugs. All these drug classes can lead to increased frailty and should in particular not be prescribed on a one-size-fits-all-basis to older people, and polypharmacy should be countered.

Our goal is for all participants to leave the meeting with the improved competence and confidence to deliver better, personalised therapy to older people, which in turn will have a positive impact on services and patient outcomes.

Course directors

  • Prof. Juan Tamargo, Spain
  • Prof. Juan Carlos Kaski, UK


Thank you for attending POP 2021.


Learning objectives

Reduction of cardiovascular disease burden by pharmacotherapy is a multistep approach, which requires to:

  • identify new potential drugs;
  • test new potential pharmacological compounds in trial setting;
  • get regulatory approval;
  • implement therapies in clinical practice.

Older patients with cardiovascular disease are often found to be undertreated. There are many reasons for this, including polypharmacy, fear of side effects, co-morbidities, frailty and sparse trial evidence of drug efficacy in the elderly. Strategies leading to the rational implementation of pharmacological therapies are therefore necessary for the subgroup of older patients with cardiovascular disease.

The specific aim of the course is to improve the practicing physician’s competence and confidence to deliver better, safer, personalised therapy for older people, which should, in turn,  have a positive impact on patient outcomes and quality of life.

Scientific programme

Download the programme

Feedback from previous courses

What past participants say
  • Over 90% of participants found the course extremely useful and useful to their daily practice
  • More than 80% rated the programme as 'excellent', with the speakers and topics as the most cited best aspects of the event
  • 95% of participants declared that the event fulfilled their educational goals and expected learning outcomes

For any questions, please contact us at